Seres Therapeutics Inc

MCRB

Equity

ISIN null / Valor 28413683

NASDAQ (2025-11-21)

USD 17.71-18.4%

Seres Therapeutics Inc
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Seres Therapeutics Inc. is a biotechnology firm focused on pioneering treatments by leveraging the human microbiome's potential to influence a broad spectrum of diseases. The company, under the leadership of individuals like David Ege, who brings extensive experience from the pharmaceutical industry, particularly in vaccine and biologics manufacturing, is at the forefront of developing a robust pipeline of microbiome therapeutics. Seres Therapeutics has established a notable collaboration with Memorial Sloan Kettering Cancer Center, aiming to enhance outcomes for cancer patients undergoing hematopoietic stem cell transplantation by preventing transplant-related infections and graft-versus-host disease. This partnership underscores the company's commitment to addressing critical areas in healthcare through innovative microbiome-based therapies. With a focus on rigorous scientific research and development, Seres is carving a niche in the biotech industry by targeting the underlying causes of diseases through modulation of the microbiome, demonstrating a promising approach to medical treatment and intervention.

Summarized from source with an LLMView SourceSector:

Net Sales Performance

In the fourth quarter of 2023, VOWST achieved net sales of approximately $10.4 million, reflecting an 11% gross-to-net reduction. For the full year 2023 since its June launch, total net sales reached approximately $19.6 million with a 13% gross-to-net reduction.

Prescription Enrollment and Patient Starts

During the fourth quarter, Seres received 1,322 completed prescription enrollment forms for VOWST, leading to 1,082 new patient starts by the end of 2023. From launch through year-end, a total of 2,833 enrollment forms were received, resulting in 2,015 new patient starts.

Healthcare Provider Adoption

Since the launch of VOWST, approximately 1,330 unique healthcare providers have submitted prescription enrollment forms, with around 65% from gastroenterology and the remaining from other specialties. Additionally, about 340 healthcare providers have prescribed VOWST to more than one patient.

Product and Pipeline Developments

VOWST received FDA approval in April 2023 as the first oral microbiome therapeutic to prevent the recurrence of Clostridioides difficile infection (CDI) in adults. The SER-155 Phase 1b Cohort 1 clinical data showed favorable results, and the placebo-controlled Cohort 2 data is anticipated in the third quarter of 2024. SER-155 has also been awarded FDA Fast Track Designation.

Operational Enhancements and Leadership

Seres completed a strategic restructuring to focus resources on the growth of VOWST, the completion of the SER-155 Phase 1b study, and ensuring long-term business sustainability. Additionally, Marella Thorell was appointed as Executive Vice President and Chief Financial Officer following the retirement of David Arkowitz.

Summarized from source with an LLMView Source

Key figures

21.0%1Y

-86.4%3Y

-97.4%5Y

Performance

107%1Y

111%3Y

108%5Y

Volatility